Principal Financial Group Inc. Has $371.78 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Principal Financial Group raised its stake in Thermo Fisher by 12.3% to 641,610 shares valued at about $371.78 million, representing 0.17% ownership at the end of the quarter.
• Thermo Fisher beat Q results (EPS $5.44 vs. $5.25; revenue $11.01B, +6.2% YoY), issued FY‑2026 EPS guidance of 24.640–25.120, and carries a consensus Buy rating with a $623.05 price target.
• The company raised its quarterly dividend to $0.47 (annualized $1.88, yield ~0.4%), while insiders sold roughly 5,800 shares (~$2.96M) in the past 90 days; insiders now own 0.33% of the stock.

Principal Financial Group Inc. raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 641,610 shares of the medical research company's stock after buying an additional 70,109 shares during the quarter. Principal Financial Group Inc. owned 0.17% of Thermo Fisher Scientific worth $371,781,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. JPL Wealth Management LLC acquired a new position in Thermo Fisher Scientific in the 3rd quarter valued at approximately $28,000. Beacon Financial Strategies CORP bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $29,000. Olistico Wealth LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $29,000. Cloud Capital Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $31,000. Finally, KERR FINANCIAL PLANNING Corp bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $38,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TMO. TD Cowen decreased their price objective on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a report on Friday, January 30th. DZ Bank began coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They set a "buy" rating and a $610.00 price objective for the company. UBS Group reaffirmed a "neutral" rating and set a $615.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Morgan Stanley reaffirmed an "overweight" rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Finally, Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a "strong-buy" rating in a research note on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $623.05.

Thermo Fisher Scientific Stock Down 1.4%

Shares of NYSE:TMO opened at $462.46 on Tuesday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company's 50-day moving average price is $496.11 and its two-hundred day moving average price is $548.03. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The firm has a market cap of $171.86 billion, a P/E ratio of 25.42, a P/E/G ratio of 2.08 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts' consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same quarter in the prior year, the firm earned $5.15 EPS. The company's revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were paid a $0.47 dividend. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. The ex-dividend date of this dividend was Friday, March 13th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is 10.34%.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company's stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the firm's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,800 shares of company stock worth $2,963,544 in the last ninety days. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.